A variety of skin diseases, autoimmune and inherited, are characterizedby the presence of blisters. In some, such as pemphigus vulgaris,blistering is the primary manifestation. In others, such aslichen planus, blisters are infrequent. Most of these diseasesare associated with substantial morbidity; a few may resultin death. Although the general approach to the treatment ofthese diseases is similar, the diagnosis of the specific diseaseis important, because the most appropriate dosage and timingof some commonly used medications vary considerably. This reviewcovers the management of the major acquired bullous diseases;diseases only rarely associated with . . . [Full Text of this Article]
Autoimmune Bullous Diseases
Systemic Corticosteroid Therapy
Topical Corticosteroid Therapy
Other Immunosuppressive Drugs
Dapsone and Related Drugs
Chrysotherapy
Plasmapheresis
Dietary Interventions
Other Therapies
Erythema Multiforme and StevensJohnson Syndrome
Systemic Corticosteroid Therapy
Other Immunosuppressive Drugs
Acyclovir and Erythema Multiforme
Other Therapeutic Options
Toxic Epidermal Necrolysis
General Principles of Treatment
Systemic Corticosteroid Therapy
Conclusions
Source Information
From the Departments of Dermatology and Epidemiology, University of North Carolina at Chapel Hill; and the National Epidermolysis Bullosa Registry both in Chapel Hill, N.C.
Address reprint requests to Dr. Fine at the Department of Dermatology, University of North Carolina at Chapel Hill, Suite 3100, Thurston Bldg., CB# 7287, Chapel Hill, NC 27599.
Iwata, Y., Komura, K., Kodera, M., Usuda, T., Yokoyama, Y., Hara, T., Muroi, E., Ogawa, F., Takenaka, M., Sato, S.
(2008). Correlation of IgE Autoantibody to BP180 With a Severe Form of Bullous Pemphigoid. Arch Dermatol
144: 41-48
[Abstract][Full Text]
Beissert, S., Werfel, T., Frieling, U., Bohm, M., Sticherling, M., Stadler, R., Zillikens, D., Rzany, B., Hunzelmann, N., Meurer, M., Gollnick, H., Ruzicka, T., Pillekamp, H., Junghans, V., Bonsmann, G., Luger, T. A.
(2007). A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Bullous Pemphigoid. Arch Dermatol
143: 1536-1542
[Abstract][Full Text]
Joly, P., Benichou, J., Lok, C., Hellot, M. F., Saiag, P., Tancrede-Bohin, E., Sassolas, B., Labeille, B., Doutre, M. S., Gorin, I., Pauwels, C., Chosidow, O., Caux, F., Esteve, E., Dutronc, Y., Sigal, M., Prost, C., Maillard, H., Guillaume, J. C., Roujeau, J. C.
(2005). Prediction of Survival for Patients With Bullous Pemphigoid: A Prospective Study. Arch Dermatol
141: 691-698
[Abstract][Full Text]
Joly, P., Roujeau, J.-C., Benichou, J., Picard, C., Dreno, B., Delaporte, E., Vaillant, L., D'Incan, M., Plantin, P., Bedane, C., Young, P., Bernard, P., the Bullous Diseases French Study Group,
(2002). A Comparison of Oral and Topical Corticosteroids in Patients with Bullous Pemphigoid. NEJM
346: 321-327
[Abstract][Full Text]
Sirois, D. A., Fatahzadeh, M., Roth, R., Ettlin, D.
(2000). Diagnostic Patterns and Delays in Pemphigus Vulgaris: Experience With 99 Patients. Arch Dermatol
136: 1569-1570
[Full Text]
SIROIS, D., LEIGH, J. E., SOLLECITO, T. P.
(2000). ORAL PEMPHIGUS VULGARIS PRECEDING CUTANEOUS LESIONS: RECOGNITION AND DIAGNOSIS. Journal of the American Dental Association
131: 1156-1160
[Abstract][Full Text]
Pandya, A. G., Dyke, C.
(1998). Treatment of Pemphigus With Gold. Arch Dermatol
134: 1104-1107
[Abstract][Full Text]
Guibal, F., Roujeau, J.-C., Stern, R. S., Weissel, M., Fine, J.-D.
(1996). Management of Acquired Bullous Skin Diseases. NEJM
334: 864-865
[Full Text]